Phaseline

Targets › XRCC1

XRCC1 (DNA repair protein XRCC1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Dec 2029.

Scaffold protein involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes. Negatively regulates ADP-ribosyltransferase activity of PARP1 during base-excision repair in order to prevent excessive PARP1 activity. (UniProt, P18887)

Open in Phaseline: the race on XRCC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Center Hospital EastCAPOXIRI
Combination chemotherapy: capecitabine (5-FU prodrug), oxaliplatin (platinum agent), and i
DPYD, TOPO1, XRCC1Phase 3Locally Advanced Rectal CancerDec 2029

Conditions

Locally Advanced Rectal Cancer (1)

Modalities

small molecule (1)

Companies

National Cancer Center Hospital East (1)

Related targets

DPYD (1) TOPO1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.